In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Houman Ashrafian, Managing Partner at SV Health Investors. Houman gives an interesting perspective into how and why biotech investment has remained robust throughout the Covid-19 pandemic. He talks to Mike about his proven track record for establishing companies and the factors he looks for when identifying interesting, investable science. Houman also talks about his work on the Dementia Discovery Fund investment committee, the opportunities they look for as well as the lessons the industry can learn from the immune-oncology revolution and how these can be applied to combat other diseases including neurodegenerative conditions, such as dementia. Houman is optimistic about where the UK is in terms of developing sciences, and what we’ll be able to achieve in this unprecedented time of science innovation. Hosted on Acast. See acast.com/privacy for more information.